BOULDER, Colo.--(BUSINESS WIRE)--Nov. 6, 2006--Array BioPharma
Inc. (Nasdaq: ARRY) today announced that data from a Phase 1 trial of
AZD6244 (ARRY-142886), a novel MEK inhibitor, will be presented at the
18th Annual EORTC-NCI-AACR Symposium on Molecular Targets and Cancer
Therapeutics to be held from November 7-10, 2006 in Prague, Czech
Republic.
Event: EORTC-NCI-AACR Symposium on Molecular Targets and
Cancer Therapeutics
Presenter: Dr. Alex A. Adjei, Senior Vice-President for Clinical
Research and Chair, Department of Medicine, Roswell Park
Cancer Institute
Title: Phase 1 Pharmacokinetic and Pharmacodynamic Study of the
MEK Inhibitor AZD6244 (ARRY-142886)
Date: Wednesday, November 8, 2006
Time: 3:00 pm CET
Location: Prague Congress Center
About AZD6244 (ARRY-142886)
AZD6244 is a potent, selective MEK inhibitor that is orally
active, that blocks signal transduction pathways implicated in cancer
cell proliferation and survival. AZD6244 has shown tumour suppressive
activity in multiple pre-clinical models of human cancer including
melanoma, pancreatic, colon, lung, and breast cancers.
About MEK Inhibition
MEK is a critical enzyme at the intersection of several biological
pathways, which regulates cell proliferation and survival as part of
the Ras/Raf/MEK/ERK pathway. Activation of the Ras/Raf/MEK/ERK pathway
has been implicated in many cancers, including lung, pancreatic,
colon, melanoma and thyroid cancer. MEK inhibition is an attractive
anti-cancer strategy as it has the potential to block inappropriate
signal transduction regardless of the upstream position of the
oncogenic aberration.
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the
discovery, development and commercialization of targeted small
molecule drugs to treat life threatening and debilitating diseases.
Our proprietary drug development pipeline is focused on the treatment
of cancer and inflammatory disease and includes clinical candidates
that are designed to regulate therapeutically important targets. In
addition, leading pharmaceutical and biotechnology companies
collaborate with Array to discover and develop drug candidates across
a broad range of therapeutic areas. For more information on Array,
please go to www.arraybiopharma.com.
CONTACT: Array BioPharma Inc.
Tricia Haugeto, 303-386-1193
ir@arraybiopharma.com
SOURCE: Array BioPharma Inc.
